MedPath

Behavioral Therapy Development for Methamphetamine Abusers

Phase 2
Withdrawn
Conditions
The Study Was Designed to Develop a Cognitive Behavioral Approach to Treating Methamphetamine Abuse in HIV Primary Care Settings
Registration Number
NCT00249678
Lead Sponsor
University of California, Los Angeles
Brief Summary

The purpose of this study is...to assess whether placing a substance abuse intervention for HIV+ methamphetamine users within an HIV medical care setting improves rates of follow-up on referral to treatment by primary care physicians; reduces drug use and sexual risk behaviors more than treatment-as-usual; and increases rates of adherence to HIV medication regimens.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
Male
Target Recruitment
Not specified
Inclusion Criteria
  1. HIV-seropositive, GBM receiving medical treatment for HIV for at least 30 days prior to signing informed consent at the UCLA CARE clinic, aged 18-65
  2. Willing to give informed consent and comply with study procedures;
  3. Willing to provide consent to contact treating physicians and pharmacies to assess adherence to HIV medications;
  4. Diagnosed with current methamphetamine abuse as determined by MINI; and
  5. Interested in seeking treatment for their methamphetamine abuse and in participating in this research project.
Exclusion Criteria
  1. Unwilling to give, or withdrawal of, informed consent;
  2. Inability to understand nature of study;
  3. A psychiatric condition that, in the principal investigator's judgment, warrants additional intervention to ensure participant safety (e.g., meets DSM-IV-TR criteria for current bipolar disorder or a psychotic disorder);
  4. Current suicidal ideation or suicide attempt within the past 3 months; and
  5. Concurrent dependence on opiates, alcohol, or benzodiazepines as determined by MINI.
  6. Total lack of any type of healthcare coverage. These potential participants will be given low-fee treatment referrals.

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Medication compliance
Craving
Addiction severity
Psychiatric interview
Sex-risk behavior
Secondary Outcome Measures
NameTimeMethod
Depression
Quality of Life

Trial Locations

Locations (3)

UCLA Medical Center

🇺🇸

Los Angeles, California, United States

UCLA, Integrated Substance Abuse Programs

🇺🇸

Los Angeles, California, United States

UCLA CARE Clinic

🇺🇸

Los Angeles, California, United States

UCLA Medical Center
🇺🇸Los Angeles, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.